{
    "clinical_study": {
        "@rank": "84026", 
        "arm_group": {
            "arm_group_label": "Primary Liver Cancer", 
            "description": "Patients that have liver masses suspicious for primary liver cancer."
        }, 
        "biospec_descr": {
            "textblock": "To collect tumor tissue from patients with liver masses suspicious for primary liver cancer."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "To collect tumor tissue from patients with liver masses suspicious for primary liver cancer.\n      The research biopsy will be used to identify biomarkers in future studies."
        }, 
        "brief_title": "Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events", 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Neoplasms", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this study patients are referred to the Department of Radiology for an image-guided\n      (either CT or ultrasound) core needle biopsy of a liver mass suspicious for primary liver\n      cancer as a part their clinical care. A written informed consent will be obtained for the\n      clinical biopsy per standard protocol. Additional core biopsy of the liver mass will be\n      performed for research purposes at the time of the clinical care biopsy. The additional\n      research biopsy is not mandatory and is subject to a separate written informed consent,\n      which will be obtained prior to the clinical biopsy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Liver mass suspicious for primary liver cancer with a diagnostic liver biopsy planned\n             as a part of clinical care\n\n          2. Age \u2265 18 years.\n\n          3. ECOG performance status 0-2\n\n          4. Adequate organ and marrow function as defined below:\n\n             INR \u2264 1.5 platelets \u2265 70,000/mcl\n\n          5. Ability to understand and the willingness to sign a written informed consent\n\n          6. Target liver mass not subcapsular in nature as determined by the participating biopsy\n             team\n\n          7. Child Pugh Turcotte score A or B\n\n        Exclusion Criteria:\n\n          1. Previous treatment for HCC\n\n          2. Any contraindication for clinical-care liver biopsy, including anti-coagulation\n             therapy that cannot be discontinued prior to biopsy or large volume ascites"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "500 patients with a liver mass suspicious for HCC"
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963949", 
            "org_study_id": "SCCC"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "number_of_groups": "1", 
        "official_title": "Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events", 
        "overall_official": {
            "affiliation": "UT Southwestern Medical Center", 
            "last_name": "Adam Yopp, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To obtain tissue from biopsy of liver masses suspicious for primary liver cancer for use in future biomarker studies.", 
            "measure": "Biopsy of Liver Masses", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963949"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "May 2014"
    }
}